In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Severely calcified mitral steno-regurgitation treated with Edwards Sapien aortic valve replacement in mitral position

Session Clinical Case Poster session 3

Speaker Martina Briani

Congress : EuroEcho-Imaging 2017

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Mitral Valve Regurgitation
  • Session type : Poster Session
  • FP Number : P735

M Briani1 , D Raspante1 , V Lavanco1 , C Vicari1 , M Cavallaro2 , M Curzi1 , L Torracca3 , RM Bragato1 , 1Istituto Clinico Humanitas, Cardiology - Milan - Italy , 2Second University of Naples, Cardiology - Naples - Italy , 3Istituto Clinico Humanitas, Cardiothoracic Surgery - Milan - Italy ,

European Heart Journal Supplements ( 2017 ) 18 ( Supplement 3 ), iii172

Mitral valve repair, when technically feasible, or valve replacement when repair is not possible, are considered the treatment of choice for patients with severe symptomatic mitral valve regurgitation. However, the presence of severe co-morbidities or severe calcification of the mitral annulus make the surgical option a high-risk one. Here we report a case in which a 61-year old woman with severe mitral steno-regurgitation and extensive valvular and sub-valvular calcification was treated with an Edwards Sapien aortic valve in the mitral position.
A 61-year old caucasian woman was admitted for progressive worsening dyspnea of grade III to IV associated with frequent episodes of palpitations. The patient had a history of mild mitral steno-regurgitation, diagnosed 15 years before. A transesophageal echocardiogram revealed the presence of severe mitral valve regurgitation (4+/4+) associated with moderate stenosis (medium gradient 9-10 mmHg, maximum gradient 22 mmHg, valvular area 1,5 cm2). Severe calcification of the posterior portion of the annulus, extending to the postero-lateral wall and to the posterior mitral valve leaflet was also described. The mitral chordae were heavily calcified and shortened, with reduction of inter-chordal space. Moderate tricuspid regurgitation due to annular dilatation was also found. The massive degree of calcification extending to both the valvular and subvalvular mitral apparatus would have rendered both valve repair and substitution technically challenging, so it was decided to proceed with the implantation of an Edwards Sapien aortic valve in the mitral position (n°26). Because of the presence of a perivalvular leak after positioning of the valve, a patch of bovine pericardium was sutured to the valve and to the atrial base. Tricuspid insufficiency was treated by placing an incomplete Contour 3D n°26 ring. Aortic crossclamp and cardiopulmonary bypass times were 118 and 145 mins respectively. Weaning from bypass did not pose any complications and the patient was transferred to the intensive care unit. The postoperative course was uneventful and the patient was dismissed after a two-week hospital stay with a predischarge transthoracic echocardiogram showing a correctly positioned mitral prosthesis with normal gradients (mean gradient 5 mmHg).
To the best of our knowledge, the placement of an Edwards Sapien aortic valve (generally used for TAVI procedures) in the mitral position has not yet been reported: further investigation seems warranted because this may represent a possible solution to these complex cases. Further follow up of this patient is needed to demonstrate the durability of the implanted valve and confirm the absence of technical complications.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are